These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23043068)

  • 1. The laboratory and the new oral anticoagulants.
    Tripodi A
    Clin Chem; 2013 Feb; 59(2):353-62. PubMed ID: 23043068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical pharmacological aspects of new oral anticoagulants].
    Haschke M
    Ther Umsch; 2012 Nov; 69(11):657-60. PubMed ID: 23117669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
    Fawole A; Daw HA; Crowther MA
    Cleve Clin J Med; 2013 Jul; 80(7):443-51. PubMed ID: 23821689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new oral anticoagulants in clinical practice.
    Gonsalves WI; Pruthi RK; Patnaik MM
    Mayo Clin Proc; 2013 May; 88(5):495-511. PubMed ID: 23639500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
    Gong IY; Kim RB
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S24-33. PubMed ID: 23790595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative management of patients on new oral anticoagulants.
    Lai A; Davidson N; Galloway SW; Thachil J
    Br J Surg; 2014 Jun; 101(7):742-9. PubMed ID: 24777590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Laboratory diagnostic with regard to new anticoagulants - monitoring and influence on coagulation tests].
    Nagler M; Wuillemin W
    Ther Umsch; 2012 Nov; 69(11):650-6. PubMed ID: 23117668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
    Tran H; Joseph J; Young L; McRae S; Curnow J; Nandurkar H; Wood P; McLintock C
    Intern Med J; 2014 Jun; 44(6):525-36. PubMed ID: 24946813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bleeding and surgery in the treatment with new oral anticoagulants. The management can be complicated by the lack of specific antidotes].
    Dalén M; Hjemdahl P; Holmström M; Ivert T
    Lakartidningen; 2014 Jun 11-17; 111(24):1064-8. PubMed ID: 25129916
    [No Abstract]   [Full Text] [Related]  

  • 10. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
    Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R
    Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rivaroxaban, dabigatran and apixaban: new anticoagulants in operative urology].
    John A; Michel MS
    Urologe A; 2014 Jun; 53(6):893-902; quiz 903. PubMed ID: 24845012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
    Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE
    Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
    Blann AD
    Br J Biomed Sci; 2014; 71(4):158-67. PubMed ID: 25562993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The laboratory and the direct oral anticoagulants.
    Tripodi A
    Blood; 2013 May; 121(20):4032-5. PubMed ID: 23564912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct oral anticoagulants--pharmacology, drug interactions, and side effects.
    Dempfle CE
    Semin Hematol; 2014 Apr; 51(2):89-97. PubMed ID: 24861792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bleeding complications under oral anticoagulation].
    Beyer-Westendorf J
    Dtsch Med Wochenschr; 2014 Dec; 139(49):2491-3. PubMed ID: 25376450
    [No Abstract]   [Full Text] [Related]  

  • 19. [Management of direct action oral anticoagulants in the peri-operative period and invasive techniques].
    Llau JV; Ferrandis R; Castillo J; de Andrés J; Gomar C; Gómez-Luque A; Hidalgo F; Torres LM;
    Rev Esp Anestesiol Reanim; 2012; 59(6):321-30. PubMed ID: 22633209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
    Barry M
    Ir Med J; 2013 Mar; 106(3):69. PubMed ID: 23951972
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.